{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:56:40Z","timestamp":1771628200998,"version":"3.50.1"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T00:00:00Z","timestamp":1411603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0107116","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T19:29:43Z","timestamp":1411673383000},"page":"e107116","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine"],"prefix":"10.1371","volume":"9","author":[{"given":"Claire","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi N.","family":"Boyda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya I.","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine C. Y.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,9,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"RM Procyshyn","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/JCP.0b013e3182a607dd","article-title":"Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility","volume":"34","author":"RM Procyshyn","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/00023210-200721090-00001","article-title":"Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia","volume":"21","author":"WG Honer","year":"2007","journal-title":"CNS Drugs"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1440-1819.2008.01869.x","article-title":"Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan","volume":"62","author":"IC Chien","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Leung JY, Pang CC, Procyshyn RM, Barr AM (2014) Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats. Vascul Pharmacol.","DOI":"10.1016\/j.vph.2014.06.003"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"CU Correll","year":"2009","journal-title":"Jama"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2010.10.014","article-title":"The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela","volume":"126","author":"T Baptista","year":"2011","journal-title":"Schizophr Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.9758\/cpn.2012.10.2.71","article-title":"Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review","volume":"10","author":"GP Reynolds","year":"2012","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"JY Leung","year":"2012","journal-title":"Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"L Tse","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"JP McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","article-title":"Pharmacological management of atypical antipsychotic-induced weight gain","volume":"22","author":"T Baptista","year":"2008","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, <etal>et al<\/etal>.. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res.","DOI":"10.1016\/j.schres.2010.07.012"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"JW Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"M Hahn","year":"2011","journal-title":"Schizophr Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"J Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/jc.2008-1815","article-title":"Effects of olanzapine and haloperidol on the metabolic status of healthy men","volume":"95","author":"S Vidarsdottir","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"VL Albaugh","year":"2011","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"KL Teff","year":"2013","journal-title":"Diabetes"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"HN Boyda","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.pnpbp.2004.08.001","article-title":"Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection","volume":"28","author":"T Baptista","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"KJ Davey","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e33548","DOI":"10.1371\/journal.pone.0033548","article-title":"Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain","volume":"7","author":"K Weston-Green","year":"2012","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"GC Smith","year":"2008","journal-title":"Diabetologia"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"HN Boyda","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"KL Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model","volume":"108","author":"AF Chintoh","year":"2009","journal-title":"Schizophr Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"S Skrede","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, <etal>et al<\/etal>.. (2011) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl).","DOI":"10.1007\/s00213-011-2397-y"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"J Ferno","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"K Weston-Green","year":"2011","journal-title":"Behav Brain Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1037\/a0031228","article-title":"Antipsychotic polypharmacy increases metabolic dysregulation in female rats","volume":"21","author":"HN Boyda","year":"2013","journal-title":"Exp Clin Psychopharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance","volume":"957","author":"T Baptista","year":"2002","journal-title":"Brain Res"},{"key":"ref34","first-page":"1521","article-title":"Lurasidone as a potential therapy for bipolar disorder","volume":"9","author":"YS Woo","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"A Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"S Leucht","year":"2013","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"HN Boyda","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/jpn.110140","article-title":"Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats","volume":"37","author":"HN Boyda","year":"2012","journal-title":"J Psychiatry Neurosci"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neuroscience.2013.10.010","article-title":"Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats","volume":"255","author":"AM Barr","year":"2013","journal-title":"Neuroscience"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1111\/j.1460-9568.2008.06233.x","article-title":"Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins","volume":"27","author":"AM Barr","year":"2008","journal-title":"Eur J Neurosci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.0953-816X.2004.03457.x","article-title":"Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia","volume":"20","author":"AM Barr","year":"2004","journal-title":"Eur J Neurosci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1152\/ajpendo.90889.2008","article-title":"Surrogate measures of insulin resistance: of rats, mice, and men","volume":"296","author":"K Mather","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1301\/nr.2003.dec.397-412","article-title":"Evaluation of insulin sensitivity in clinical practice and in research settings","volume":"61","author":"LU Monzillo","year":"2003","journal-title":"Nutr Rev"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2010.07.008","article-title":"The oral glucose tolerance test (OGTT) revisited","volume":"22","author":"E Bartoli","year":"2011","journal-title":"Eur J Intern Med"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, <etal>et al<\/etal>.. (2005) Postprandial glucose regulation: new data and new implications. Clin Ther 27 Suppl B: S42\u201356.","DOI":"10.1016\/j.clinthera.2005.11.020"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1152\/ajpendo.00645.2007","article-title":"Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage","volume":"294","author":"R Muniyappa","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Hughey CC, Hittel DS, Johnsen VL, Shearer J (2011) Hyperinsulinemic-euglycemic clamp in the conscious rat. J Vis Exp.","DOI":"10.3791\/2432"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e53459","DOI":"10.1371\/journal.pone.0053459","article-title":"Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine","volume":"8","author":"HN Boyda","year":"2013","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"AF Chintoh","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/0269881109348167","article-title":"Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them","volume":"24","author":"S Park","year":"2010","journal-title":"J Psychopharmacol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"T Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"V Simon","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"S Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/070674370004500302","article-title":"Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench","volume":"45","author":"S Kapur","year":"2000","journal-title":"Can J Psychiatry"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2006.04.004","article-title":"Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats","volume":"51","author":"AM Barr","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-011-2251-2","article-title":"Interaction of mGlu2\/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats","volume":"217","author":"M Horiguchi","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/WNR.0b013e328352de40","article-title":"5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux","volume":"23","author":"M Huang","year":"2012","journal-title":"Neuroreport"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"VL Albaugh","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance","volume":"59","author":"PJ Martins","year":"2011","journal-title":"Diabetes"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Smith GC, Vickers MH, Shepherd PR (2011) Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem.","DOI":"10.3109\/13813455.2011.576681"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-009-1593-5","article-title":"Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats","volume":"206","author":"M Victoriano","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A parametric analysis of olanzapine-induced weight gain in female rats","volume":"181","author":"GD Cooper","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2006.09.009","article-title":"Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain","volume":"551","author":"BM Patil","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pnpbp.2013.10.006","article-title":"Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine","volume":"48","author":"HN Boyda","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.euroneuro.2013.07.011","article-title":"Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model","volume":"24","author":"MK Hahn","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.schres.2007.11.027","article-title":"Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment","volume":"100","author":"AM Barr","year":"2008","journal-title":"Schizophr Res"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"von Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, Jones P (2009) Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl: 15\u201321.","DOI":"10.1111\/j.1600-0447.2008.01309.x"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S1461145713000795","article-title":"Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats","volume":"17","author":"HN Boyda","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","article-title":"Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis","volume":"26","author":"M De Hert","year":"2012","journal-title":"CNS Drugs"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","author":"M Ogasa","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"ref71","unstructured":"Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, <etal>et al<\/etal>.. (2013) Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr: 1\u201310."},{"key":"ref72","doi-asserted-by":"crossref","first-page":"e43244","DOI":"10.1371\/journal.pone.0043244","article-title":"Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance","volume":"7","author":"EM Girault","year":"2012","journal-title":"PLoS One"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0107116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T21:50:18Z","timestamp":1650232218000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0107116"}},"subtitle":[],"editor":[{"given":"Franco","family":"Folli","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,25]]},"references-count":72,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0107116","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,25]]}}}